Last reviewed · How we verify
Beovu (BROLUCIZUMAB)
Beovu works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and reducing vascular permeability and inflammation.
Beovu (Brolucizumab) is a medication developed by Novartis Pharmaceuticals Corporation, targeting vascular endothelial growth factor A (VEGF-A). It is used to treat exudative age-related macular degeneration and macular edema due to diabetes mellitus. Beovu works by binding to VEGF-A, preventing its interaction with its receptor and subsequently reducing vascular permeability and inflammation. As of 2023, Beovu remains a patented medication with its commercial status unchanged. Key safety considerations include potential increased risk of intraocular inflammation and retinal vasculitis.
At a glance
| Generic name | BROLUCIZUMAB |
|---|---|
| Sponsor | Novartis |
| Target | Vascular endothelial growth factor A |
| Modality | Monoclonal antibody |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2019 |
Mechanism of action
Brolucizumab is human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF110, VEGF121, and VEGF165), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Approved indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
Common side effects
- Vision blurred
- Cataract
- Conjunctival hemorrhage
- Eye pain
- Vitreous floaters
- Intraocular inflammation
- Intraocular pressure increased
- Retinal hemorrhage
- Vitreous detachment
- Conjunctivitis
- Retinal pigment epithelial tear
- Corneal abrasion
Key clinical trials
- the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration (NA)
- Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. (PHASE4)
- Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PHASE3)
- Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD (NA)
- Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
- Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy (PHASE3)
- Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (PHASE4)
- Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beovu CI brief — competitive landscape report
- Beovu updates RSS · CI watch RSS
- Novartis portfolio CI